Paolo Tarantino: LAG3 blockade adds upon PD1 blockade in melanoma
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared a post by Akhil Santhosh, at on X:
“LAG3 blockade clearly adds upon PD1 blockade in melanoma, with 20% reduction in the risk of death.
Could it also improve outcomes in other cancer types?”
Quoting Akhil Santhosh’s post:
“The 3-year results of relativity 047 out in Journal of Clinical Oncology.
Nivolumab and relatlimab continues to impress. Toxicity profile better than nivo ipi. Interestingly, at the 3 year follow up, upper bound of HR 95% ci is less than 1 for overall survival.”
Authors: Hussein Tawbi et al.
More posts featuring Paolo Tarantino.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023